Clustering Of Diabetes Subgroups May Aid Outcome Predicting
Executive Summary
This year's EASD meeting in Lisbon heard calls to re-categorize type 2 diabetes into novel subsets, as data suggest the approach could lead to better targeted treatments.
You may also be interested in...
Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016
Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now on the road to recovery.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.